
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience is attractive fundamentally because its precision-psychiatry strategy uses EEG and other biomarkers to enrich for responders, which should improve trial signal quality and raise the odds of clinical success versus broad, noise-prone development. The lead programs look meaningfully de-risked: ALTO-300 builds on an EU-approved, generally safe agomelatine backbone with an expected 1H27 readout and roughly 50% biomarker enrichment, while ALTO-207 is supported by independent pramipexole data and a differentiated ondansetron-enabled titration strategy in a three-trial PACE program. Financially, about $338 million of pro forma cash is expected to fund operations through 2030, giving the company runway to reach multiple 2027 catalysts, including ALTO-300 in 1H27, ALTO-100 in mid-2027, and PACE-1 in 2H27.
Bears say
Alto Neuroscience is facing a weak fundamental setup because real-world pramipexole dosing is materially below the Phase 2 PAX-D trial, with an average maximum daily dose of 0.71 mg versus 2.3 mg and 78% titrating more slowly than labeled, raising doubt that ALTO-207 can translate clinical promise into commercial use. Its core monetization challenge is that pramipexole and ondansetron are both generic, so the asset must justify value as a combined product despite off-label substitution friction and payer barriers, while prior ALTO-100 execution also disappointed when the Phase 2b trial missed its primary endpoint. Financially, spending is already rising, with R&D at $22.1 million in 2Q26 versus $13.1 million in 2Q25 and net loss widening to $27.6 million, and the need for $150 million to $200 million of annual equity raises in 2027E–2029E points to significant future dilution.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alto Neuroscience Inc (ANRO) Forecast
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares